Heart metabolic disturbances in cardiovascular diseases

Archives of Medical Research

Volumn 34, Issue 2, 2003, Pages 89-99

  Carvajal, Karla ^a   Moreno Sánchez, Rafael ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Creatine kinase; Energy metabolism; Glycolysis; Heart metabolism; L carnitine; Oxidative phosphorylation

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARNITINE; CREATINE KINASE; CREATININE; DICHLOROACETIC ACID; GLUCOSE; INSULIN; MITOCHONDRIAL ENZYME; PROPIONYLCARNITINE; RANOLAZINE; TRIMETAZIDINE;

ANGINA PECTORIS; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; CARNITINE DEFICIENCY; CITRIC ACID CYCLE; DEPLETION; DIABETES MELLITUS; ENERGY; ENERGY METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLYCOLYSIS; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE REPERFUSION; HEART PERFORMANCE; HEART SURGERY; HUMAN; ISCHEMIC HEART DISEASE; METABOLIC DISORDER; METABOLISM; MITOCHONDRION; MUSCULAR DYSTROPHY; OXIDATION; OXIDATIVE PHOSPHORYLATION; OXYGEN SUPPLY; REPERFUSION INJURY; REVIEW;

EID: 0037359748     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0188-4409(03)00004-3     Document Type: Review

References (118)

1. Rodrigues B., McNeill J. The diabetic heart. metabolic causes for the development of a cardiomyopathy Cardiovasc Res. 26:1992;913-922.
2. Lopaschuck G.D., Wambolt R.B., Barr R.L. An imbalance between glycolysis and glucose oxidation is a possible explanation of the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther. 264:1993;135-144.
3. Wallimann T. Dissecting the role of creatine kinase. Curr Biol. 4:1994;42-46.
4. Ferrari R., Pepi P., Ferrari F., Nesta F., Benigno M., Visioli O. Metabolic derangement in ischemic heart disease and its therapeutic control. Am J Cardiol. 82:1998;2K-13K.
5. Starling R.C., Hammer D.F., Altschuld R.A. Human myocardial ATP content and in vivo contractile function. Mol Cell Biochem. 180:1998;171-177.
6. Vogt A., Kübler W. Heart failure. is there an energy deficit contributing to contractile dysfunction? Basic Res Cardiol. 93:1998;1-10.
7. Wang Y., Meadowe A., Longo N. Abnormal sodium stimulation of carnitine transport in primary carnitine deficiency. J Biol Chem. 275:2000;20782-20786.
8. Carvajal K., Baños G. Myocardial function and effect of serum in isolated heart from hypertriglyceridemic and hypertensive rats. Clin Exp Hypertens. 24:2002;235-248.
9. Broderick T.L., Quinney H.A., Lopaschuk G.D. Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart. J Biol Chem. 267:1992;3758-3763.
10. Allard M.F., Schönekess B.O., Henning S.L., English D.R., Lopaschuk G.D. The contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied heart. Am J Physiol. 267:1994;H742-H750.
11. Schönekess B.O., Allard M.F., Lopaschuck G.D. Propionyl L-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circ Res. 77:1995;726-734.
12. El Alaoui-Talibi Z., Guendouz A., Moravec M., Moravec J. Control of oxidative metabolism in volume-overloaded rat hearts. effect of propionyl-L-carnitine Am J Physiol. 272:1997;H1615-H1624.
13. Lehman J.J., Kelly D.P. Gene regulatory mechanism governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev. 7:2002;175-185.
14. Ravingerova T., Neckar J., Kolar F., Steka R., Volkovova K., Ziegelhöffer A., Styk J. Ventricular arrhythmias following coronary artery occlusion in rats. is the diabetic heart less or more sensitive to ischaemia? Basic Res Cardiol. 96:2001;160-168.
15. De Sousa E., Veksler V., Minajeva A., Kaasik A., Mateo P., Mayoux E., Hoerter J., Bigard X., Serrurier B., Ventura-Clapier R. Subcellular creatine kinase alterations. Implications in heart failure. Circ Res. 85:1999;68-76.
16. Dzeja P.P., Redfield M.M., Burnett J.C., Terzic A. Reduced activity of enzymes coupling ATP-generating with ATP-consuming processes in the failing myocardium. Mol Cell Biochem. 201:1999;33-40.
17. Garvey W.T., Hardin D., Huhaszova M., Domínguez J.H. Effects of diabetes on myocardial glucose transport system in rats. implications of diabetic cardiomyopathy Am J Physiol. 264:1993;H837-H844.
18. Rodrigues B., Grassby P.F., Battell M.L., Lee S.Y.N., McNeill J.H. Hypertriglyceridemia in experimental diabetes. relationship to cardiac dysfunction Can J Physiol Pharmacol. 72:1994;447-455.
19. Randle P.J., Priestman D.A., Mistry S., Halsall A. Mechanisms modifying glucose oxidation in diabetes mellitus. Diabetologia. 37:1994;S155-S161.
20. Hall J., Stanley W.C., Lopaschuk G.D., Wisneski J.A., Pizzurro R., Hamilton C.D., McCormack J.G. Impaired pyruvate oxidation but normal glucose uptake in diabetic pig heart during dobutamine-induced work. Am J Physiol. 271:1996;H2320-H22329.
21. Flarsheim C.E., Grupp I.L., Matlib A. Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart. Am J Physiol. 271:1996;H192-H202.
22. Rodrigues B., Cam M.C., Kong J., Goyal R.K., McNeill J.H. Strain differences in susceptibility to streptozotocin-induced diabetes. effects on hypertriglyceridemia and cardiomyopathy Cardiovasc Res. 34:1997;199-205.
23. Stanley W., Lopaschuk G.D., McCormack J.G. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res. 34:1997;25-33.
24. Wu P., Sato J., Zhao Y., Jaskiewicz J., Popov K.M., Harris R.A. Starvation and diabetes increase the amount of pyruvate dehydrogenase kinase isoenzyme 4 in rat heart. Biochem J. 329:1998;197-201.
25. Rodrigues B., Cam M.C., McNeill J.H. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem. 180:1998;53-57.
26. Mahgoub M.C.A., Abd-Elfattah A.S. Diabetes mellitus and cardiac function. Mol Cell Biochem. 180:1998;59-64.
27. Aasum E., Belke D.D., Severson D.L., Riemersma R.A., Cooper M., Andreassen M., Larsen T.S. Cardiac function and metabolism in type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol. 283:2002;H949-H957.
28. Yazaki Y., Isobe M., Takahashi W., Kitabayashi H., Nishiyama O., Sekiguchi M., Takemura T. Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123 I BMIPP SPECT. correlation with clinicopathological findings and clinical course Heart. 81:1999;153-159.
29. Ishinno K., Botker E., Clausen T., Hetzer R., Sehested J. Myocardial adenine nucleotides, glycogen, and Na, K+ATPase in patients with idiopathic dilated cardiomyopathy requiring mechanical circulatory support. Am J Cardiol. 83:1999;396-399.
30. Bassingthwaighte J.B., Li Z. Heterogeneities in myocardial flow and metabolism. exacerbation with abnormal excitation Am J Cardiol. 83:1999;7H-12H.
31. Rumsey W., Abbot B., Bertelsen D., Msallamaci K., Nelson D., Erecinska M. Adaptation to hypoxia alters energy metabolism in rat heart. Am J Physiol. 276:1999;H7-H80.
32. Argaud L., Ovize M. Pertubations du métabolisme myocardique au cours de l'isquémie et de la reperfusion. Arch Mal Coeur. 93:2000;87-90.
33. Opie L.H. Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction. Am J Cardiol. 36:1975;938-953.
34. Lucas D.T., Szweda L.I. Declines in mitochondrial respiration during cardiac reperfusion. age-dependent inactivation of α-ketoglutarate dehydrogenase Proc Natl Acad Sci USA. 98:1999;6689-6693.
35. Braunwald E. Control of myocardial oxygen consumption. Am J Cardiol. 27:1971;416-432.
36. Neely J.R., Morgan H.E. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol. 36:1974;413-459.
37. Zierler K.L. Fatty acids as substrates for the heart and skeletal muscle. Circ Res. 38:1976;459-463.
38. Montini J., Bagby G.J., Spitzer J.J. Importance of exogenous substrates for the energy production of adult rat heart myocytes. J Mol Cell Cardiol. 13:1981;903-911.
39. Phelps R.L., Metzger B.E., Freinkel N. Carbohydrate metabolism in pregnancy. XVII. Diurnal profiles of plasma glucose, insulin, free fatty acids, triglycerides, cholesterol, and individual acids in the late normal pregnancy. Am J Obstet Gynecol. 140:1981;730-736.
40. Bartelds B., Gratama J.W.C., Knoester H., Takens J., Smid G.B., Aarnoudse J.G., Heymans H.S.A., Kuipers J.R.G. Perinatal changes in myocardial supply and flux of fatty acids, carbohydrates, and ketone bodies in lambs. Am J Physiol. 274:1998;H1962-H1969.
41. Laughlin M.R., Taylor J., Chesnick A.S., DeGroot M., Balaban R.S. Pyruvate and lactate metabolism in the in vivo dog heart. Am J Physiol. 264:1993;H2068-H2079.
42. Jeffrey F.M.H., Diczku V., Sherry A.D., Malloy C.R. Substrate selection in the isolated working rat heart. effects of reperfusion, afterload, and concentration Basic Res Cardiol. 90:1995;388-396.
43. Goodwin G.W., Taylar C.S., Taegtmeyer H. Regulation of energy metabolism of heart during acute increase in heart work. J Biol Chem. 272:1988;29530-29539.
44. King L.M., Opie L.H. Glucose and glycogen utilisation in myocardial ischemia. Changes in metabolism and consequences for the myocyte. Mol Cell Biochem. 180:1998;3-26.
45. Medina H.M. The role of lactate as energy substrate for brain during the early neonatal period. Biol Neonate. 48:1991;237-244.
46. Saggerson E.D. Carnitine acyltransferase activities in rat liver and heart measured with palmitoyl-CoA and octanoyl-CoA. Biochem J. 202:1982;397-405.
47. De Vries Y., Arvidson D.N., Waterham H.R., Cregg J.M., Woldegiogis G. Functional characterization of mitochondrial carnitine palmitoyltransferases I and II expressed in the yeast Pichia pastors. Biochemistry. 36:1997;5285-5292.
48. Mills S.H., Foster D.W., McGarry J.D. Effects of pH on the interaction of substrates and malonyl-CoA with mitochondrial carnitine palmitoyltransferase. Biochem J. 219:1984;601-608.
49. Eaton S., Bartlett K., Pourfarzam M. Mammalian mitochondrial β-oxidation. Biochem J. 320:1996;345-357.
50. Abdel-aleem S., St Lous J, Hendrickson SC, El-Shewy HM, El-Dawy K, Taylor DA, Lowe JE. Regulation of carbohydrate and fatty acid utilisation by L-carnitine during cardiac development and hypoxia. Mol Cell Biochem. 180:1998;95-103.
51. Dizon J., Burkhoff D., Tauskela J., Whang J., Cannon P., Katz J. Metabolic inhibition in the perfused rat heart. evidence for glycolytic requirement for normal sodium homeostasis Am J Physiol. 274:1998;H1082-H1089.
52. Hall J.L., Sexton W., Stanley W.C. Differential regulation of myocardial glucose transporters with exercise training in streptozotocin-induced diabetic rats. J Appl Physiol. 78:1994;76-81.
53. Fischer Y., Böttcher U., Eblenkamp M., Thomas J., Jüngling E., Rösen P., Kammermeier H. Glucose transport and glucose transporter GLUT4 are regulated by products of intermediary metabolism in cardiomyocytes. Biochem J. 321:1997;629-638.
54. Hansford R.G., Cohen L. Relative importance of pyruvate dehydrogenase interconversion and feed-back inhibition in the effect of fatty acids on pyruvate oxidation by rat heart mitochondria. Arch Biochem Biophys. 191:1978;65-81.
55. Latipää P.M., Peuhurienn K.J., Hiltunen J.K., Hassinen I.E. Regulation of pyruvate dehydrogenase during infusion of fatty acids of varying chain lengths in the perfused rat heart. J Mol Cell Cardiol. 17:1985;1161-1171.
56. Liedtke A.J., DeMaisson L., Eggleston A.M., Cohen L.M., Nelis S.H. Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium. Circ Res. 89:1988;1019-1023.
57. Johnston D., Lewandowski D.E. Fatty acid metabolism and contractile function in the reperfused myocardium. Circ Res. 68:1991;714-725.
58. Carvajal K., Baño S., Moreno-Sánchez R. Impairment of glucose metabolism and energy transfer in the hypertriglyceridemic rat heart. Mol Cell Biochem. in press:2003.
59. Park O., Cesar D., Faix D., Wu K., Shackleton C.H.L., Hellerstein M.K. Mechanisms of fructose-induced hypertriglyceridaemia in the rat. Biochem J. 282:1992;753-757.
60. Shafrir E. The plurimetabolic syndrome in animals. models for experimentation, their implications and relation to NIDDM Crepaldi G., Tiengo A., Manzato E. Diabetes, obesity and hyperlipidemias. V. The plurimetabolic syndrome:1993;Excerpta Medica, Amsterdam, The Netherlands. 45-55.pp.
61. Sugden M.C., Fryer L.G.D., Holness M. Regulation of hepatic pyruvate dehydrogenase kinase by insulin and dietary manipulation in vivo. Studies with the euglycaemic and hyperinsulinaemic clamp. Biochim Biophys Acta. 1316:1996;114-180.
62. Kerbey A.L., Caterson I.D., Williams P.F., Turtle J.R. Proportion of active dephosphorylated pyruvate dehydrogenase complex in heart and isolated heart mitochondria is decreased in obese hyperinsulinaemic mice. Biochem J. 217:1984;117-121.
63. Caterson I.D., Tylor K.W. Islet cell function in gold thioglucose-induced obesity in mice. Diabetologia. 23:1982;119-123.
64. Caterson I.D., Astbury L.D., Williams P.F., Vanner M.A., Cooney G.J., Turtle J.R. The activity of the pyruvate dehydrogenase complex in heart and liver from mice during the development of obesity and insulin resistance. Biochem J. 243:1987;549-553.
65. French T.J., Goode A.E., Holness M.J., Maclennan P.A., Sugden M.C. The relationship between changes in lipid fuel availability and tissue fructose 2,6-bisphosphate concentrations and pyruvate dehydrogenase complex activities in the fed state. Biochem J. 256:1988;935-939.
66. Baños G., Carvajal K., Cardoso G., Zamora J., Franco M. Vascular reactivity and effect of serum in a rat model of hypertriglyceridemia and hypertension. Am J Hypertens. 10:1997;379-388.
67. Wambolt R.B., Henning S.L., English D.R., Dyachkova Y., Lopaschuk G.D., Allard M.F. Glucose utilization and glycogen turnover accelerated in hypertrophied rat hearts during severe low-flow ischemia. J Mol Cell Cardiol. 31:1999;493-502.
68. Brenstrom B., Liedtke A.J., Nellis S.H. Mechanism of substrate preference for oxidative metabolism during early myocardial reperfusion. Am J Physiol. 259:1990;H317-H323.
69. Brenstrom B., Nellis S.H., Liedtke A.J. Metabolic oxidation of glucose during early myocardial reperfusion. Circ Res. 64:1989;1094-1101.
70. Cargnoni A., Ceconi C., Curello S., Benigno M., Willem de Jong J., Ferrari R. Relation between energy metabolism, glycolysis, noradrenaline release and duration of ischemia. Mol Cell Biochem. 160(161):1994;187-194.
71. Vanoverschelde J.L., Janier M.F., Bakke J.E., Marshall D.R., Bergmann S.R. Rate of glycolysis during ischemia determines extent of ischemic injury and functional recovery after reperfusion. Am J Physiol. 267:1994;H1785-H1794.
72. West K.M., Ahuja M.M.S., Bennett P.H. The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from WHO multi-national study. Diabetes Care. 6:1983;361-369.
73. Carvajal K., El Hafidi M., Baños G. Myocardial damage due to ischemia and reperfusion injury. role of calcium overload and free radicals J Hypertens. 17:1999;1607-1616.
74. El Hafidi M., Baños G. In vivo lipid oxidation in sugar-induced rat hypertriglyceridemia and hypertension. Hypertension. 30:1997;624-628.
75. Liu Q., Clanachan A.S., Lopaschuk G.D. Acute affects of triiodothyronine on glucose and fatty acid metabolism during reperfusion of ischemic rat hearts. Am J Physiol. 275:1998;E392-E399.
76. Veitch K., Maisin L., Hue L. Trimetazidine effects on the damage to mitochondrial functions caused by ischemia and reperfusion. Am J Cardiol. 76:1995;25B-30B.
77. Shofield R.S., Hill J.A. Role of metabolically active drugs in the management of ischemic heart disease. Am J Cardiovasc Drugs. 1:2001;23-35.
78. Remondino A., Rosenblatt-Velin N., Montessuit I.T., Papageorgiou I., Dorsaz P., Jorge-Costa M., Lerch R. Altered expression of proteins of metabolic regulation during remodelling of the left ventricle after myocardial infarction. J Mol Cell Cardiol. 32:2000;2025-2034.
79. Brunold C., El Alaoui-Talibi Z., Moravec M., Moravec J. Palmitate oxidation by the mitochondria from volume-overloaded rat hearts. Mol Cell Biochem. 180:1998;117-128.
80. Jung W., Dietze G.J. 31P Nuclear magnetic resonance spectroscopy. a non-invasive tool to monitor metabolic abnormalities in left ventricular hypertrophy in humans Am J Cardiol. 83:1999;19H-24H.
81. Schoonjans K., Staels B., Auwerx J. Role of the peroxisome proliferator-activated recepetor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 37:1996;907-925.
82. Reedy J.K., Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha. an adaptive metabolic system Annu Rev Nutr. 2:2001;193-230.
83. Braissant O., Foufelle F., Scotto C., Dauca M., Whali W. Differential expression of peroxisome proliferator-activated receptors (PPARs). tissue distribution of PPAR-α, -β and -γ in the adult rat Endocrinology. 137:1996;354-366.
84. Vamecq J., Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 354:1999;141-148.
85. Kersten S., Desvergne B., Whali W. Roles of PPARs in health and disease. Nature. 405:2000;421-424.
86. Jonkers I.J., Mohrschladt M.F., Westendorp R.G., van der Laarse A., Smelt A.H. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation. reversal with bezafibrate therapy in a randomized controlled trial Am J Med. 112:2002;275-280.
87. Fruchart J.C., Staels B., Duriez P. PPARS, metabolic disease and atherosclerosis. Pharmacol Res. 44:2001;345-352.
88. Watts G.F. Treating patients with low HDL-cholesterol. choices, issues and opportunities Curr Control Cardiovasc Med. 2:2001;118-122.
89. Nakamura T., Sugihara H., Kinoshita N., Toneyama S., Azuma A., Nakagawa M. Can serum carnitine levels distinguish hypertrophic cardiomyopathy from hypertensive hearts? Hypertension. 36:2000;215-219.
90. Calvani M., Reda E., Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol. 95:2000;75-83.
91. Lopaschuk G.D., Spafford M.A., Davies N.J., Wall S.R. Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia. Circ Res. 66:1990;546-553.
92. Terada R., Matsubara T., Koh N., Nakamura J., Hotta N. Effects of propionyl-L-carnitine on cardiac dysfunction in streptozotocin-diabetic rats. Eur J Pharmacol. 357:1998;185-197.
93. Scholte H.R., Rodrigues-Pereira R., de Jongue P.C., Luyt-Houwin I.E., Hedwing M., Verduin M., Ross J.D. Primary carnitine deficiency. J Clin Chem Clin Biochem. 28:1990;351-357.
94. Indiveri C., Iacobazzi V., Giangregorio N., Palmieri F. The mitochondrial carnitine carrier protein. cDNA cloning, primary structure and comparison with other mitochondrial transport proteins Biochem J. 321:1997;713-719.
95. Paulson D.J. Carnitine deficiency-induced cardiomyopathy. Mol Cell Biochem. 180:1998;33-41.
96. Whitmer J.T. L-carnitine treatment improves cardiac performance and restores high energy phosphate pools in cardiomyopathic Syrian hamster. Circ Res. 61:1987;396-408.
97. Rottenberg H. Decoupling of oxidative phosphorylation. Biochim Biophys Acta. 1018:1990;1-17.
98. Schild L., Reinheckel T., Wiswedel I., Aaugustin W. Short-term impairment of energy production in isolated rat liver mitochondria by hypoxia/reoxygenation. involvement of oxidative protein modification Biochem J. 328:1997;205-210.
99. Janero D.R., Hreniuk D., Sharif H.M. Hydroperoxide-induced oxidative stress impairs heart muscle cell carbohydrate metabolism. Am J Physiol. 266:1994;C179-C188.
100. Nakai N., Sato Y., Oshida Y., Yoshimura A., Fujitsuka N., Sugiyama S., Shimomura Y. Effects of aging on the activities of pyruvate dehydrogenase complex and its kinase in rat heart. Life Sci. 60:1997;2309-2314.
101. 2+ activation of PDH. Am J Physiol. 276:1999;H149-H158.
102. Spindler M., Saupe K.W., Christe M.E., Sweeney L., Seidman C.E., Seidman J.G., Ingwall J.S. Diastolic dysfunction and altered energetics in the αMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest. 101:1998;1775-1783.
103. Soboll S., Brdiczka D., Jahnke D., Schmidt A., Schlattner U., Wendt S., Wyss M., Walliman T. Octamer-dimer transitions of mitochondrial creatine kinase in heart diseases. J Mol Cell Cardiol. 31:1999;857-866.
104. Kaasik A., Minajeva A., De Sousa E., Ventura-Clapier R., Veksler V. Nitric oxide inhibits cardiac energy production via inhibition of mitochondrial creatine kinase. FEBS Lett. 444:1999;75-77.
105. Merante F., Mickle D.A.G., Weisel R.D., Li R., Tumiati L.C., Rao V., Williams W.G., Robinson B.H. Myocardial aerobic metabolism is impaired in a cell culture model of cyanotic heart disease. Am J Physiol. 275:1998;H1673-H1681.
106. Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 86:2000;580-588.
107. Wambolt R.B., Lopaschuk G.D., Brownsey R.W., Allard M.F. Dichloroacetate improves postischemic function of hypertrophied rat hearts. J Am Coll Cardiol. 36:2000;1378-1385.
108. Lopaschuk G.D. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. Am J Cardiol. 82:1988;14K-17K.
109. Breveti G., di Lisa F., Perna S., Menabó R., Barbato R., Martone V.D., Siliprandi N. Carnitine-related alterations in patients with intermittent claudication. Circulation. 93:1996;1685-1689.
110. Keith V., Maisin L., Hue L. Trimetazidine effects on the damage to mitochondrial functions caused by ischemia and reperfusion. Am J Cardiol. 76:1995;25B-30B.
111. Lopaschuk G.D., Stanley W.C. Manipulation of energy metabolism in the heart. Science Med. 6:1997;42-51.
112. Pogatsa G. Metabolic energy metabolism in diabetes. therapeutic implications Coron Artery Dis. 1:2001;S29-S33.
113. Lopaschuk G.D. Optimizing cardiac energy metabolism. how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis. 1:2001;S8-S11.
114. Brass E.P. Supplemental carnitine and exercise. Am J Clin Nutr. 72:2000;618S-623S.
115. Xiao C.Y., Chen M., Hara A., Hashizume H., Abiko Y. Palmitoyl-L-carnitine modifies the myocardial levels of high-energy phosphates and free fatty acids. Basic Res Cardiol. 92:1997;320-330.
116. 2+ handling and survival in mdx skeletal muscle cells. FEBS Lett. 439:1998;357-362.
117. Neubauer S., Remkes H., Spindler M., Horn M., Wiesmann F., Prestle J., Walzel B., Ertl G., Hasenfuss G., Walliman T. Downregulation of the Na+-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation. 100:1999;1847-1850.
118. Walliman T, Schlattner U, Guerrero L, Dolder M. The phosphocreatine circuit and creatine supplementation, both come of age! In: Mori A, Ishida M, Clark JF, editors. Guanidino compounds in biology and medicine: 5. Victoria, Melbourne, Australia: Blackwell Science Asia Pty., 1999. pp. 118-129.